This mutation is also observed in melanomas, and BRAF and MEK inhibitors such as vemurafenib, dabrafenib, and trametinib have revolutionized the treatment of these neoplasms, with promising results also for PCPs (25) (Figure 3). This evidence concerns the gene MAP2K7 and neoplasm.